Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Gilead Reports Interim Data From Phase 2 LONESTAR Study

Company Plans to Initiate Phase 3 Study Evaluating Eight and 12 Weeks of Therapy with Sofosbuvir and Ledipasvir for the Treatment of Chronic Hepatitis C.

Published
03 May 2013
From
Gilead press release
Daclatasvir + asunaprevir + BMS-791352 looks promising as interferon-free combination

An all-oral regimen containing three next-generation antivirals taken for either 12 or 24 weeks produced sustained virological response in more than 90% of previously untreated genotype 1

Published
02 May 2013
By
Liz Highleyman
Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets

A new analysis from Frost & Sullivan, "Analysis of European Hepatitis B and C Therapeutics Markets" finds that the Hepatitis B market earned revenues of $1.26 billion in 2012 and estimates this to reach $1.89 billion in 2019, while the Hepatitis C market is projected to expand from $2.40 billion to $3.66 billion over the same time period.

Published
01 May 2013
From
PR Newswire
Compassionate access to new hepatitis C drugs an "emergency" for European patients

European governments must move quickly to ensure that compassionate use arrangements are put into place to allow access to new hepatitis C drugs for people with cirrhosis,

Published
30 April 2013
By
Keith Alcorn
Second-generation protease inhibitor faldaprevir cures up to 80% of hepatitis C

A second-generation hepatitis C protease inhibitor, faldaprevir, cured up to 80% of previously untreated people with genotype 1 hepatitis C virus (HCV) infection when combined with pegylated

Published
30 April 2013
By
Keith Alcorn
Second-generation HCV protease inhibitor simeprevir pushes triple therapy cure rate up to 80%

A second-generation hepatitis C protease inhibitor, simeprevir, cured around 80% of previously untreated people with genotype 1 hepatitis C virus (HCV) infection when combined with pegylated interferon

Published
30 April 2013
By
Keith Alcorn
Triple-drug HCV therapy comes with high risk of serious adverse events for people with cirrhosis

Currently available triple therapies for hepatitis C carry a high risk of serious side-effects for people in the most urgent need of treatment, and these patients have

Published
30 April 2013
By
Keith Alcorn
Hep C quad regimens quashed, but some components go forward

A pair of four-drug interferon-based hepatitis C regimens worked well, but further study has been halted after a few patients experienced serious adverse events, according to a

Published
29 April 2013
By
Liz Highleyman
Daclatasvir + sofosbuvir offers hepatitis C rescue therapy after current standard of care

An interferon-free regimen of daclatasvir plus sofosbuvir, with or without ribavirin, cured all previously treated hepatitis C (HCV) patients who did not respond to interferon-based triple therapy

Published
29 April 2013
By
Liz Highleyman
Gilead-Bristol Hepatitis C Combo Cures 100% of Patients in Study

A combination of hepatitis C drugs from Gilead Sciences Inc. (GILD) and Bristol-Myers Squibb Co. (BMY) cured 100 percent of patients in a trial, showing the success of a cocktail that doctors say they want yet may never be approved.

Published
28 April 2013
From
Businessweek

Filter by country